Table 1 Included study characteristics
First author (year, country) | Study period | Study design | No. of patients | Median follow-up (months) | ER definition (months) | Overall recurrence rate (%) | ER rate (%) | 5-year OS in ER group (%) | Inclusion criteria | Exclusion criteria |
|---|---|---|---|---|---|---|---|---|---|---|
Bhogal,2015 [18],UK | 2004–2006 | PC | 243 | 58 | 18 | 52.7 | 38.3 | - | LR for CRLM | - |
Chen,2022 [19], China | 2008–2020 | RC | 144 | - | 11 | - | - | - | Histologic CRLM, LR after NAC; | NAR, lack of f/p data |
Dai,2021 [15], China | 2012–2019 | RC | 202 | - | 6 | 77.7 | 43.6 | - | Synchronous CRLM, adenocarcinoma, curative-intent surgery | recurrent CRLM or remnant lesions, lack of f/p data |
Deng,2023 [20], China | 2008–2020 | RC | 323 | - | 13 | - | - | - | Clinical or histological CRLM; simultaneous curative-intent resection | Lack of f/p data, other severe diseases |
Finkelstein, 2008 [21],USA | 1995–2002 | PC | 100 | 31 | 12 | 52 | 30.0 | - | LR for CRLM | Extrahepatic disease |
Imai,2016 [22],France | 1990–2012 | PC | 846 | 57.6 | 8 | 78.8 | 44.8 | 11.1 | Curative surgery for CRLM, a f/u > 2 years | Died of postoperative complications |
Inoue,2020 [23], Japan | 2001–2017 | RC | 295 | - | 6 | 64.1 | 29.8 | 45 | LR for CRLM | Noncurative resection |
Jung,2016 [24], Korea | 1990–2011 | RC | 277 | 45.1 | 6 | - | 10.8 | 33.8 | LR for CRLM | R2 resection |
Kaibori,2012 [14], Japan | 1993–2007 | RC | 119 | 31 | 24 | 53.8 | 45.4 | 24.2 | Curative resection for CRLM | R2 resection |
Lalmahomed,2015 [25], Netherlands | 2008–2012 | RC | 151 | 28 | 12 | 76.2 | 54.3 | - | Adult, adenocarcinoma, CRLM, LR or open RFA | Noncurative resection, extrahepatic metastasis, lack of f/p data |
Lin,2018 [26], China | 1999–2016 | RC | 307 | 31.7 | 6 | 57.3 | 16.0 | - | CRLOM, adenocarcinoma, R0 resection, a f/u > 6 months | Extrahepatic metastasis, R1 or R2 resection, loss to f/p |
Liu,2015 [27], China | 2000–2014 | RC | 303 | 40 | 12 | 63.4 | 47.9 | 16 | LR for CRLM | - |
Malik,2007 [28], UK | 1993–2003 | PC | 430 | 33 | 6 | 66.7 | 20.0 | 22 | LR for CRLM, a f/u > 2 years | NAC, repeated LR |
Mao,2017 [29],China | 2007–2015 | PC | 255 | 28.6 | 6 | 65.1 | 34.1 | 11.8 | Curative-intent LR for histological CRLM, a f/u > 6 months | Extrahepatic metastases, R2 resection, RFA, died within 90 days after surgery, repeated LR |
Narita,2015, [30]Japan | 2007–2009 | PC | 184 | - | 6 | 49.5 | 22.3 | - | R0 LR for CRLM | Extrahepatic recurrence within 6 months, R1/R2 resection |
Sakai,2021 [16],Japan | 2001–2016 | RC | 229 | - | 12 | 73.4 | 42.4 | - | Initial LR for CRLM | R2 resection |
Sun,2014 [31],China | 2000–2013 | PC | 152 | 22 | 6 | 63.1 | 24.9 | - | - | - |
Tabchouri,2018 [32],France | 2000–2016 | PC | 273 | 41 | 6 | 72 | 22.8 | - | Curative-intent LR for CRLM | A f/u < 6 months |
Tanaka,2014 [33], Japan | 1992–2011 | RC | 405 | 31 | 4 | 40.7 | 8.6 | 27.4 | Curative resection for CRLM | R2 resection |
Viganò,2014 [34], Italy, Multicenter | 1998–2009 | PC | 6025 | 34.4 | 6 | 45.4 | 10.6 | 26.9 | LR for CRLM, a f/u > 6 months | R2 resection, f/u < 6 months, two-stage LR, operative mortality |
Viganò,2022 [12], Italy | 2004–2017 | PC | 484 | 34 | 3 | 75.2 | 11.6 | 17.3 | LR for CRLM | Repeated LR, died within 90 days, R2 resection, loss to f/p |
Watanabe,2020 [35], Japan | 2004–2016 | PC | 643 | 44.2 | 6 | 44.3 | 20.7 | 24 | Initial LR for CRLM | R2 resection |
Wong,2022 [36], Australia | 2007–2017 | PC | 194 | 85.3 | 6 | 74.7 | 29.9 | 28.8 | Initial curative‐intent LR for CRLM, a f/u > 6 months | R2 resection, a f/u < 6 months, died within 30 days |
Yamashita,2011 [37], Japan | 1986–2007 | RC | 121 | - | 12 | 67.8 | 43.0 | 20 | Initial curative‐intent LR for CRLM | RFA or MCT |